Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Prenetics Global LimitedNASDAQ: PRE
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$9.52M, compared with -$11M a year earlier. Trailing-twelve-month EBITDA was -$51.68M.
Context
- EBITDA amounted to 34.8% of revenue in FY2025, down 133.6 pp from a year earlier.
- EBITDA grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 8 analysts of -$38.9M (-20.8%) for the fiscal year ending Dec 2026, a slowdown from the +37.6% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$9.52M+61.2% QoQ
- Last fiscal yearDec 2025
- -$32.19M+37.6% YoY
- LTMMar 2026
- -$51.68M+9.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +13.5% | -31.3% | -44.8 pp |
| 1 year | +37.6% | -20.8% | -58.4 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (32.19M) USD
- Year-over-year change
- +37.6%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (32.19M) | +37.6% |
| FY2024 | 2024-12-31 | (51.57M) | -7.7% |
| FY2023 | 2023-12-31 | (47.9M) | +78.0% |
| FY2022 | 2022-12-31 | (218.04M) | -4.2% |
| FY2021 | 2021-12-31 | (209.16M) | — |
EBITDA vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's LTM Mar 2026 EBITDA of -$51.68M is the 8th highest of the 11 companies compared; the peer median is -$40.74M.
- Its year-over-year change of +9.1% is the 5th highest of 11, against a peer median of +7.4%.
- EBITDA amounts to 45.4% of revenue for PRE, versus a peer median of 81.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$20.95M | +5.5% | — | 46.7% | |
| LTM Mar 2026 | -$22.06M | +62.9% | — | 28.2% | |
| LTM Mar 2026 | -$25.7M | +34.0% | — | 17.0% | |
| LTM Mar 2026 | -$34.64M | +5.7% | — | 107.3% | |
| LTM Mar 2026 | -$37.85M | +9.1% | — | 200.6% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | -$43.64M | +63.0% | — | 10.0% |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$45.4M | +19.5% | — | 2329.5% |
| LTM Mar 2026 | -$51.68M | +9.1% | — | 45.4% | |
| LTM Mar 2026 | -$63.7M | -188.7% | — | 56.4% | |
| LTM Mar 2026 | -$117.46M | -66.2% | — | 339.9% | |
| LTM Mar 2026 | -$262.46M | -2046.7% | — | 8872.8% | |
| Peer median (excluding PRE) | -$40.74M | +7.4% | — | 81.8% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.53M | 13.16M | 21.74M | 30.62M | 92.39M |
| Cost of Revenue | 8.93M | 9.55M | 12.91M | 15.22M | 43.6M |
| Gross Profit | 3.6M | 3.62M | 8.83M | 15.4M | 48.79M |
| Gross Margin | 28.7% | 27.5% | 40.6% | 50.3% | 52.8% |
| Research & Development | 6.39M | 5.99M | 11.66M | 10.92M | 5.13M |
| Selling, General & Admin | 53.67M | 64.08M | 49.68M | 55.37M | 79.8M |
| Operating Expenses | 60.26M | 69.64M | 60.74M | 63.54M | 86.92M |
| Depreciation & Amortization | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M |
| EBITDA | (209.16M) | (218.04M) | (47.9M) | (51.57M) | (32.19M) |
| EBITDA Margin | -1668.9% | -1656.3% | -220.3% | -168.4% | -34.8% |
| Operating Income | (56.66M) | (66.02M) | (51.91M) | (48.14M) | (38.13M) |
| Operating Margin | -452.1% | -501.5% | -238.7% | -157.2% | -41.3% |
| Interest Income | 201 | 472K | 3.92M | 2.04M | 1.04M |
| Interest Expense | 42.23K | 242K | 119.66K | 203K | 241K |
| Other Income / Expenses | (159.89M) | (159.8M) | (4.76M) | (9.56M) | 1.92M |
| Income Before Tax | (216.55M) | (225.82M) | (56.67M) | (57.7M) | (36.21M) |
| Pre-Tax Margin | -1727.9% | -1715.4% | -260.6% | -188.4% | -39.2% |
| Income Tax Expense | 2.57M | (245K) | (269.36K) | (7.87M) | 34K |
| Net Income | (174.01M) | (190.45M) | (62.72M) | (46.3M) | (37.71M) |
| Net Margin | -1388.4% | -1446.8% | -288.5% | -151.2% | -40.8% |
| EPS (Basic) | (47.04) | (37.57) | (5.58) | (3.64) | (2.68) |
| EPS (Diluted) | (47.04) | (37.57) | (5.58) | (3.64) | (2.68) |
| Weighted Avg Shares | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M |
| Weighted Avg Shares (Diluted) | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.